NOS3 Genotype

Your blood vessels depend on a tiny signaling molecule called nitric oxide to relax, open up, and keep blood flowing smoothly. The gene that controls how your body makes that signal is called NOS3 (endothelial nitric oxide synthase), and the version you inherited can quietly nudge your lifetime risk for heart attack, high blood pressure, stroke, and several other vascular conditions.

This is an exploratory marker, not a diagnosis. The version of NOS3 you carry is fixed at birth and shifts your odds by a modest amount, not a verdict. But because it points to how well your vessels can produce one of the body's most important protective signals, it adds a piece of context that routine cholesterol and blood pressure checks cannot show on their own.

What This Test Actually Reads

The test looks at well studied spots in the NOS3 gene. The three most commonly studied are Glu298Asp (also called G894T or rs1799983), a promoter variant called -786T>C (rs2070744), and a repeated stretch of DNA in intron 4. The Glu298Asp variant is the only common change that swaps one amino acid for another in the finished enzyme. Mechanistic studies have suggested it leads to altered placement of the enzyme inside cells, impaired response to blood flow, and lower baseline nitric oxide production, though large reviews note the precise functional role of this variant remains unclear because the relevant phenotypes are hard to measure directly. The -786C variant has been shown in reporter studies and in failing human heart tissue to reduce how much of the gene's message gets made, although the size and direction of that effect appears to depend on context and on which other nearby variants travel with it.

Different labs may report different variants on their panel, and each variant carries its own pattern of associations. Treat your result as a profile of a few specific spots in one gene, not as a complete read of your vascular genetics.

Heart Attack and Coronary Artery Disease Risk

This is the best studied area for NOS3. A widely cited 2006 pooled review found per-allele odds ratios of about 1.17 for Glu298Asp, 1.17 for -786T>C, and 1.12 for the intron 4 variant, meaning each risk copy nudges coronary heart disease odds up by about 12 to 17 percent. A more recent 2014 meta-analysis confirmed all three variants are linked to coronary artery disease and reported somewhat larger pooled effects for Glu298Asp depending on the genetic model used.

One UK study reported a more dramatic finding: people homozygous for the Asp298 version had higher odds of angiographically confirmed coronary artery disease and myocardial infarction compared with non-carriers. Effects this large have not been consistently replicated, and reviewers have noted that smaller early studies with striking results may have inflated the true effect, which is why most describe the typical clinical impact as modest.

What this means for you: if you carry one or two risk copies, your baseline coronary risk is somewhat higher than someone without them, but the size of that shift is small enough that it will not show up in a single number. The practical move is to be more aggressive about the levers you can actually pull, including ApoB, blood pressure, and inflammation.

Hypertension and Vascular Function

NOS3 variants have been tied to blood pressure regulation, but the story is messy and population dependent. In one Chinese cohort, variants called rs1808593 and rs7830 were linked to essential hypertension, while a separate Australian study found no association between any NOS3 markers and hypertension itself, only with body mass index and lipids.

In essential hypertension patients, carrying the -786C allele was associated with a markedly higher risk of atherosclerotic plaques on the carotid arteries, suggesting the variant matters more for vascular damage than for blood pressure numbers alone. A large prospective cohort of more than 18,000 women did not find consistent associations between common NOS3 polymorphisms and blood pressure progression or new-onset hypertension.

Stroke

A genome-wide meta-analysis identified NOS3 as one of three new loci linked to stroke risk, with blood pressure changes appearing to mediate part of that effect. A separate meta-analysis in Asian populations found that the intron 4 variant, -786T>C, and Glu298Asp all showed associations with ischemic stroke risk, and a Tunisian case-control study reached similar conclusions across all three variants.

Type 2 Diabetes and Diabetic Kidney Disease

In a Chinese Han cohort of nearly 1,000 people, the AA genotype at rs3918188 was significantly linked to higher type 2 diabetes risk, and rs1800783 was linked to higher risk of diabetic nephropathy in people with type 2 diabetes. An updated meta-analysis found that minor alleles at rs2070744 and rs1799983 were associated with greater susceptibility to diabetic kidney disease.

Another study reported that carrying risk alleles at NOS3 together with risk alleles at two other vascular genes (CETP and ANGPTL8) was associated with sharply elevated odds of having both type 2 diabetes and cardiovascular disease. NOS3 status is best read as part of a larger genetic picture, not in isolation.

Heart Failure and Cardiomyopathy

In a study of 469 patients with congestive heart failure, those carrying the Asp298 variant had poorer event-free survival, particularly among people whose heart failure was not caused by coronary disease. In African Americans with heart failure, NOS3 genotype was linked to differences in blood pressure and left ventricular remodeling. An Indian study reported that a specific combination of variants increased dilated cardiomyopathy risk roughly sevenfold.

Other Associations

Several other conditions have been linked to NOS3 variants in specific populations. The rs1799983 variant has been linked to primary open-angle glaucoma in a Saudi cohort, particularly in men, while the rs2070744C allele appears protective against severe retinopathy of prematurity. Variants have also been linked to congenital heart disease susceptibility, more severe COVID-19 in younger patients without chronic lung disease, recurrent miscarriage, and modified susceptibility to invasive breast cancer with lymph node involvement.

Not every association has held up. A Spanish study of 680 people found no link between rs2070744 and multiple sclerosis, and a study of differentiated thyroid cancer found no significant link between common NOS3 variants and key clinical outcomes.

A Counterintuitive Finding in Athletes

You may see NOS3 promoted as a performance gene. In one meta-analysis, the rs2070744 T allele was more common in endurance athletes than in non-athletes. In elite swimmers, the -786T allele, the Glu298 allele, and the G-T haplotype were enriched in long-distance specialists, while the Asp298 allele was more common in female sprinters.

One way to reconcile these findings: NOS3 is not a simple good gene or bad gene marker. The same variant that nudges up coronary risk in middle age may also shape muscle blood flow patterns in ways that suit either endurance or sprint performance. The variants likely act as biological dials whose effect depends on what tissue is using nitric oxide, what age you are, and what stressors you are under. A finding that one allele helps marathoners does not cancel a finding that the same allele raises heart attack odds decades later. This is an interpretation drawn across studies, not a directly tested conclusion.

What a Result Looks Like

This is a one-time test. The genotype you inherited at conception will be the same if you retest at age 30, 50, or 80. There is no trend to follow at the gene itself. What evolves over your lifetime is the downstream phenotype that the gene helps shape, including your blood pressure, ApoB, hs-CRP (high-sensitivity C-reactive protein), and carotid wall thickness. Those are the numbers worth tracking on a regular cadence.

A practical schedule: take the NOS3 test once. Then, if you carry one or more risk variants, treat that as a reason to monitor your dynamic vascular markers more aggressively. Baseline ApoB, blood pressure, and inflammation now; recheck in 3 to 6 months if you are making changes; then at least annually thereafter.

What to Do With an Unexpected Result

If you carry one or more NOS3 risk variants, the next step is not to retest the gene. The next step is to tighten the workup around your vascular system. That means getting ApoB rather than just standard cholesterol, adding Lp(a) (lipoprotein a) for inherited heart attack risk, checking hs-CRP for vascular inflammation, and getting a real read on blood pressure with multiple measurements or 24-hour monitoring.

If you have a personal or family history of early heart disease, stroke, or unexplained hypertension, share the result with a preventive cardiologist or lipidologist. A NOS3 variant on its own is rarely the deciding factor, but combined with a family history of premature cardiovascular disease, an elevated ApoB, or imaging findings like coronary calcium, it can shift the threshold for starting earlier treatment.

What This Test Will Not Tell You

A NOS3 panel reads only the specific variants the lab has chosen to detect. A negative result does not rule out other rare variants in the same gene or in the dozens of other genes that influence vascular biology. Risk variant frequencies also vary by ancestry, so the clinical meaning of a particular allele depends in part on the population it was studied in. And carrying a risk variant does not mean disease will happen. Most people with NOS3 risk alleles never develop coronary disease, especially if their lifestyle and dynamic markers stay clean.

One large review of NOS3 polymorphisms concluded that using these variants alone for predictive testing in healthy people is unlikely to be useful. Treat your result as one input into a broader vascular risk profile, not as a verdict.